Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.13 - $1.88 $8,249 - $13,724
-7,300 Reduced 97.33%
200 $0
Q2 2024

Aug 14, 2024

BUY
$1.3 - $3.01 $2,080 - $4,816
1,600 Added 27.12%
7,500 $10,000
Q1 2024

May 15, 2024

BUY
$1.71 - $3.07 $7,695 - $13,815
4,500 Added 321.43%
5,900 $13,000
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.35 $1,112 - $1,880
-800 Reduced 36.36%
1,400 $2,000
Q3 2023

Nov 14, 2023

SELL
$1.45 - $3.35 $1,740 - $4,020
-1,200 Reduced 35.29%
2,200 $3,000
Q2 2023

Aug 14, 2023

BUY
$1.89 - $3.86 $378 - $772
200 Added 6.25%
3,400 $10,000
Q1 2023

May 15, 2023

BUY
$1.97 - $3.58 $2,364 - $4,296
1,200 Added 60.0%
3,200 $7,000
Q4 2022

Feb 14, 2023

BUY
$2.78 - $8.09 $5,560 - $16,180
2,000 New
2,000 $6,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $228M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.